Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

[1]  Jinming Yu,et al.  PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.

[2]  C. Horak,et al.  Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Tarhini.  Immunotherapy of Melanoma. , 2016, Current molecular pharmacology.

[4]  R. Sullivan,et al.  Melanoma driver mutations and immune therapy , 2016, Oncoimmunology.

[5]  M. Atkins,et al.  Advances in immunotherapy for melanoma , 2016, BMC Medicine.

[6]  D. Davar,et al.  Adjuvant Therapy of Melanoma. , 2016, Cancer treatment and research.

[7]  A. Sapino,et al.  Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status: A Systematic Review and Meta-analysis. , 2015, JAMA dermatology.

[8]  Arati Sharma,et al.  Current State of Animal (Mouse) Modeling in Melanoma Research , 2015, Cancer growth and metastasis.

[9]  W. Sharfman,et al.  Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma , 2015, Cancer biology & therapy.

[10]  Baolan Li,et al.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer , 2015, Scientific Reports.

[11]  N. Vigneron.  Human Tumor Antigens and Cancer Immunotherapy , 2015, BioMed research international.

[12]  M. P. de Macedo,et al.  Evaluation of Melanoma Features and Their Relationship with Nodal Disease: The Importance of the Pathological Report , 2015, Tumori.

[13]  E. Panaitescu,et al.  Survival rates of patients with metastatic malignant melanoma , 2014, Journal of medicine and life.

[14]  G. Murphy,et al.  Stem cells and targeted approaches to melanoma cure. , 2014, Molecular aspects of medicine.

[15]  R. Botella-Estrada,et al.  Correlation of histologic regression in primary melanoma with sentinel node status. , 2014, JAMA dermatology.

[16]  David Escors,et al.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. , 2014, New journal of science.

[17]  Thomas M. Schmitt,et al.  Re‐adapting T cells for cancer therapy: from mouse models to clinical trials , 2014, Immunological reviews.

[18]  J. Lister,et al.  A Conditional Zebrafish MITF Mutation Reveals MITF Levels Are Critical for Melanoma Promotion vs. Regression In Vivo , 2013, The Journal of investigative dermatology.

[19]  Nikolas K. Haass,et al.  Modeling Melanoma In Vitro and In Vivo , 2013, Healthcare.

[20]  V. Sondak,et al.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Senetta,et al.  Favourable prognostic role of regression of primary melanoma in AJCC stage I–II patients , 2013, The British journal of dermatology.

[22]  J. Haanen.  Immunotherapy of melanoma , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[23]  L. Eapen,et al.  Spontaneous regression of metastatic melanoma after inoculation with tetanus-diphtheria-pertussis vaccine. , 2013, Current oncology.

[24]  T. Hieken,et al.  Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes , 2013, Melanoma research.

[25]  H. Schmidt,et al.  Regression in cancer following fever and acute infection , 2013, Acta oncologica.

[26]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[27]  C. Slingluff,et al.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma , 2012, Melanoma research.

[28]  E. Nagore,et al.  Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma. , 2012, Archives of dermatology.

[29]  S. Petrescu,et al.  Spectrum of morphologic alterations of regression in cutaneous melanoma--potential for improving disease prognosis. , 2012, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[30]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[31]  G. Dranoff,et al.  Experimental mouse tumour models: what can be learnt about human cancer immunology? , 2011, Nature Reviews Immunology.

[32]  A. Stromberg,et al.  Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. , 2011, American journal of surgery.

[33]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[34]  A. Stromberg,et al.  Regression Does Not Predict Nodal Metastasis or Survival in Patients with Cutaneous Melanoma , 2011, The American surgeon.

[35]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Elder,et al.  High Lymphatic Vessel Density and Lymphatic Invasion Underlie the Adverse Prognostic Effect of Radial Growth Phase Regression in Melanoma , 2011, The American journal of surgical pathology.

[37]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[38]  F. Hodi,et al.  Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .

[39]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[40]  P. Payoux,et al.  Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients , 2009, The British journal of dermatology.

[41]  E. Nagore,et al.  CONTROVERSIAS EN DERMATOLOGÍA Regresión en el melanoma: problemas en su definición e implicación pronóstica , 2009 .

[42]  S. Almenar,et al.  [Problems in defining melanoma regression and prognostic implication]. , 2009, Actas dermo-sifiliograficas.

[43]  R. Labianca,et al.  Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. , 2009, European journal of cancer.

[44]  M. Frank,et al.  Antitumor Immunity and Cancer Stem Cells , 2009, Annals of the New York Academy of Sciences.

[45]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[46]  S. Mocellin,et al.  Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI) , 2009, Annals of Surgical Oncology.

[47]  Oliver Hofmann,et al.  Genome-wide analysis of cancer/testis gene expression , 2008, Proceedings of the National Academy of Sciences.

[48]  R. Phelps,et al.  Complete Regression of Primary Malignant Melanoma , 2008, The American Journal of dermatopathology.

[49]  R. Gutzmer,et al.  Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[50]  R. Cecchi,et al.  Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. , 2008, Chirurgia italiana.

[51]  G. Walz,et al.  Sensitive cilia set up the kidney , 2007, Nature Medicine.

[52]  Hong Tang,et al.  Adaptive immune cells temper initial innate responses , 2007, Nature Medicine.

[53]  C. Kaur,et al.  The correlation of regression in primary melanoma with sentinel lymph node status , 2007, Journal of Clinical Pathology.

[54]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[55]  K. Busam,et al.  Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy , 2007, Annals of Surgical Oncology.

[56]  D. Elder,et al.  Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma , 2006, Cancer.

[57]  Lisa M. Ebert,et al.  Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1 , 2006, Immunology and cell biology.

[58]  L. Chin,et al.  Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice , 2006, Genesis.

[59]  M. Mihm,et al.  Prognosticators of melanoma, the melanoma report, and the sentinel lymph node , 2006, Modern Pathology.

[60]  Bruce R Smoller,et al.  Histologic criteria for diagnosing primary cutaneous malignant melanoma , 2006, Modern Pathology.

[61]  M. Cook,et al.  The significance of inflammation and regression in melanoma , 2006, Virchows Archiv A.

[62]  O. Csuka,et al.  Relationship between sentinel lymph node status and regression of primary malignant melanoma , 2005, Melanoma research.

[63]  C. Cockerell,et al.  Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. , 2005, Journal of the American Academy of Dermatology.

[64]  C. Ichim,et al.  Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy , 2005, Journal of Translational Medicine.

[65]  D. Ivan,et al.  The immunopathology of regression in benign lichenoid keratosis, keratoacanthoma and halo nevus. , 2004, Clinical medicine & research.

[66]  D. Elston.  Mechanisms of regression. , 2004, Clinical medicine & research.

[67]  N. Cavale,et al.  Five years of sentinel node biopsy for melanoma: the St George's Melanoma Unit experience. , 2004, British journal of plastic surgery.

[68]  C. Figdor,et al.  Presence and localization of T‐cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells , 2004, The Journal of pathology.

[69]  K. Hou‐Jensen,et al.  Partial regression in thin primary cutaneous malignant melanomas clinical stage I , 1985, Virchows Archiv A.

[70]  P. Leboit,et al.  Regressing and Regressed Melanoma , 2004 .

[71]  W. Greer,et al.  Partial Regression of Primary Cutaneous Melanoma: Is There an Association with Sub-Clinical Sentinel Lymph Node Metastasis? , 2003, The American Journal of dermatopathology.

[72]  A. Dobozy,et al.  Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas , 2003, The British journal of dermatology.

[73]  B. Bastian.  Hypothesis: a role for telomere crisis in spontaneous regression of melanoma. , 2003, Archives of dermatology.

[74]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[75]  J. Sosman,et al.  Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. , 2002, Cancer.

[76]  C. Shea,et al.  Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. , 2002, Archives of dermatology.

[77]  S. Menzies,et al.  Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1 , 2001, International journal of cancer.

[78]  T. Di Pucchio,et al.  Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.

[79]  V. Cerundolo,et al.  Immunotherapy of melanoma , 2001, Immunology.

[80]  C. Printz.  Spontaneous regression of melanoma may offer insight into cancer immunology. , 2001, Journal of the National Cancer Institute.

[81]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[82]  J. J. Coleman,et al.  Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma , 2000, Cancer.

[83]  N. Restifo,et al.  The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.

[84]  H. Byers,et al.  Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. , 1998, Hematology/oncology clinics of North America.

[85]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[86]  I. Avinoach,et al.  Metastatic Malignant Melanoma with Spontaneous and Complete Regression of the Primary Lesion , 1994 .

[87]  M. Mihm,et al.  Histologic regression in malignant melanoma: an interobserver concordance study , 1993, Journal of cutaneous pathology.

[88]  Ceballos Pi,et al.  Spontaneous regression of cutaneous tumors. , 1993 .

[89]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[90]  L. Brogelli,et al.  The prognostic significance of histologic regression in cutaneous melanoma , 1992, Melanoma research.

[91]  K. Mclaren,et al.  Histological regression in primary cutaneous melanoma: recognition, prevalence and significance , 1992, Histopathology.

[92]  R. Dowden,et al.  Complete spontaneous regression of cutaneous primary malignant melanoma. , 1992, Plastic and reconstructive surgery.

[93]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[94]  S. McCarthy,et al.  Thin regressing malignant melanoma: Significance of concurrent regional lymph node metastases , 1989, Histopathology.

[95]  D. Reintgen,et al.  Lethal “Thin” Malignant Melanoma: Identifying Patients at Risk , 1988, Annals of surgery.

[96]  T. K. Das Gupta,et al.  Thin malignant melanomas with regression and metastases. , 1987, Archives of dermatology.

[97]  A. Cochran,et al.  Recurrence potential of thin primary melanomas , 1986, Cancer.

[98]  M. S. Blois,et al.  Regression in malignant melanoma. A histologic feature without independent prognostic significance , 1985, Cancer.

[99]  H. Wanebo,et al.  Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. , 1985, Archives of dermatology.

[100]  R. Sagebiel.  Regression and other factors of prognostic interest in malignant melanoma. , 1985, Archives of dermatology.

[101]  H. Wanebo,et al.  Thin (<1 mm) Melanomas of the Extremities Are Biologically Favorable Lesions Not Influenced by Regression , 1985 .

[102]  V. McGovern,et al.  Prognosis in patients with thin malignant melanoma: influence of regression , 1983, Histopathology.

[103]  A. Kopf,et al.  Regression in malignant melanoma. , 1983, Journal of the American Academy of Dermatology.

[104]  R. Paladugu,et al.  Biologic behavior of thin malignant melanomas with regressive changes. , 1983, Archives of surgery.

[105]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: Prognostic Histopathological Features Comparing Clark's and Breslow's Staging Methods , 1978, Annals of surgery.

[106]  M. S. Blois,et al.  The regressing thin malignant melanoma. A distinctive lesion with metastatic potential , 1978, Cancer.

[107]  Nathanson.  Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. , 1976, National Cancer Institute monograph.

[108]  V. McGovern.  SPONTANEOUS REGRESSION OF MELANOMA , 1975, Pathology.

[109]  J. Stehlin,et al.  Spontaneous regression of primary malignant melanomas with regional metastases , 1965, Cancer.

[110]  W. Cole,et al.  Spontaneous Regression of Cancer: preliminary Report , 1956 .

[111]  W. C. Sumner.  Spontaneous regression of melanoma. Report of a case , 1953 .